Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from Needham & Company LLC
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at ...
H.C. Wainwright maintains $45 target on Cartesian stock
H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...
Buy Rating for Cartesian Therapeutics: Promising Phase 3 Prospects for Descartes-08 in Treating Myasthenia Gravis
Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...
PharmaTimes1d
Cartesian Therapeutics announces FDA agreement for new trial
Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...
Nasdaq2d
Cartesian Therapeutics Receives FDA Agreement on Phase 3 Trial Design for Descartes-08 in Myasthenia Gravis
Cartesian Therapeutics, Inc. announced that it received FDA agreement on the design of its upcoming Phase 3 AURORA trial for Descartes-08, an mRNA cell therapy intended for treating myasthenia ...
Yahoo Finance3d
Cartesian Therapeutics, Inc. (RNAC)
Trial on track to commence in 1H25FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage ...
Yahoo Finance2d
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering ...